YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Lakefront Receives Transparency Notification from Bank of America·globenewswire.com Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notif…
Lakefront Biotherapeutics Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront")…
Lakefront Biotherapeutics Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront")…
Lakefront Biotherapeutics (LKFT) has a "meaningful opportunity" with its asset gamgertamig for the t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Lakefront Biotherapeutics Mechelen, Belgium; September 22, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront"…
Key Points Interested in Lakefront Biotherapeutics American Depositary Shares? Here are five stocks we like better. Lakefront plans to start registrational trials for gamgertamig in ITP and AIHA in 2027, with additional autoimmune basket s…
Lakefront Biotherapeutics Mechelen, Belgium; 15 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront")…
Lakefront Biotherapeutics Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront")…
Lakefront Biotherapeutics Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare…
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthu…
Lakefront Biotherapeutics Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") an…
Lakefront Biotherapeutics Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transpar…
Lakefront Biotherapeutics Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug…
CHENGDU, China, Aug. 20, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026. Guided by a clear dual-engine driven strategy, the company demonstrate…
Lakefront Biotherapeutics Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") an…
Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig appro…
Lakefront Biotherapeutics Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") ann…
Lakefront Biotherapeutics Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") ann…
Lakefront Biotherapeutics Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") anno…
Lakefront Biotherapeutics Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development…
Lakefront Biotherapeutics Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") anno…
Lakefront Biotherapeutics Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") anno…
Lakefront Biotherapeutics Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian tr…
Lakefront Biotherapeutics Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") anno…
Lakefront Biotherapeutics Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") ann…
Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurch…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Investors may be wondering whether Lakefront Biotherapeutics at €24.94 is starting to look like v…
Lakefront Biotherapeutics Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announcedthe launch of a share repurchase program (the “Program”), under which the C…
Lakefront Biotherapeutics Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announcedthat Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role suppo…
Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announcedthat Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company’s strategi…
Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, a strategic move designed to bolster their inflammati…
Lakefront Biotherapeutics Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET –…
Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET – Gilead Sciences, Inc. (Na…
– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases – FOSTER CITY, Calif. & MECHELEN, Belgium, June 04, 2026--(BUSINESS WIRE)--Gilead Sciences,…
Bedrijven gaan samenwerken aan de ontwikkeling van gamgertamig, een potentieel first-in-class en best-in-class T-cel-engager voor auto-immuunziekten Foster City, Californië en Mechelen, België; 4 juni 2026, 22.15 CET –Gilead Sciences, Inc.…